Jump to content

କାନାବିଡିଓଲ

ଉଇକିପିଡ଼ିଆ‌ରୁ
(Cannabidiolରୁ ଲେଉଟି ଆସିଛି)
Not to be confused with Cannabinol or Cannabinodiol.
କାନାବିଡିଓଲ
Clinical data
Trade namesEpidiolex, Epidyolex
SynonymsCBD, cannabidiolum, (−)-cannabidiol[୩]
AHFS/Drugs.commonograph
MedlinePlusa618051
data
Pregnancy
category
Routes of
administration		By mouth[୨]
Legal status
Legal status
Pharmacokinetic data
Bioavailability• By mouth: 6% (fasted)[୮]
• Inhaled: 31% (11–45%)[୯]
Elimination half-life18–32 hours[୧୦]
Identifiers
  • 2-[(1R,6R)-6-Isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol
ECHA InfoCard100.215.986 Edit this at Wikidata
Chemical and physical data
FormulaC21H30O2
Molar mass୩୧୪.୪୭ g·mol−1
3D model (JSmol)
Melting point66 °C (151 °F)
Solubility in waterinsoluble mg/mL (20 °C)
  • Oc1c(c(O)cc(c1)CCCCC)[C@@H]2\C=C(/CC[C@H]2\C(=C)C)C
  • InChI=1S/C21H30O2/c1-5-6-7-8-16-12-19(22)21(20(23)13-16)18-11-15(4)9-10-17(18)14(2)3/h11-13,17-18,22-23H,2,5-10H2,1,3-4H3/t17-,18+/m0/s1{PubChem}
  • Key:QHMBSVQNZZTUGM-ZWKOTPCHSA-N{PubChem}
  (verify)
<span title="International nonproprietary name (INN): <nowiki>Mr. Ibrahem/Cannabidiol</nowiki>">Mr. Ibrahem/Cannabidiol
Clinical data
Trade names Epidiolex, Epidyolex
Other names CBD, cannabidiolum, (−)-cannabidiol[୧୧]
AHFS/Drugs.com Monograph
MedlinePlus a618051
License data
Pregnancy

category
  • <abbr class="country-name" title="<nowiki>Australia</nowiki>">AU: B2[୧୨]
Routes of

administration 		By mouth[୧୨]
Drug class Cannabinoid[୧୨]
Legal status
Legal status
  • <abbr class="country-name" title="<nowiki>Australia</nowiki>">AU: S3 (Pharmacist only)
  • <abbr class="country-name" title="<nowiki>Canada</nowiki>">CA: Unscheduled
  • <abbr class="country-name" title="<nowiki>United Kingdom</nowiki>">UK: POM (Prescription only) [୧୨][୧୨]
  • <abbr class="country-name" title="<nowiki>United States</nowiki>">US: Schedule V / Rx-only[୧୨][୧୩]
  • <abbr class="country-name" title="<nowiki>European Union</nowiki>">EU: Rx-only [୧୨]
Pharmacokinetic data
Bioavailability • By mouth: 6% (fasted)[୧୨]

• Inhaled: 31% (11–45%)[୧୨]
Elimination half-life 18–32 hours[୧୨]
Identifiers
  • 2-[(1R,6R)-6-Isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol
Chemical and physical data
Formula C21H30O2
Molar mass 314.469 g·mol−1
3D model (JSmol)
Melting point 66 °C (151 °F)
Solubility in water insoluble
  • Oc1c(c(O)cc(c1)CCCCC)[C@@H]2\C=C(/CC[C@H]2\C(=C)C)C
  • InChI=1S/C21H30O2/c1-5-6-7-8-16-12-19(22)21(20(23)13-16)18-11-15(4)9-10-17(18)14(2)3/h11-13,17-18,22-23H,2,5-10H2,1,3-4H3/t17-,18+/m0/s1{PubChem}
  • Key:QHMBSVQNZZTUGM-ZWKOTPCHSA-N{PubChem}
  (verify)

କାନାବିଡିଓଲ ( ସିବିଡି ) ହେଉଛି ଏକ କାନନାବିନଏଡ୍ ଯାହା ଔଷଧ ଭାବାରେ ବାତ, ଟ୍ୟୁବରସ ସ୍କ୍ଲେରୋସିସ୍ କମ୍ପ୍ଲେକ୍ସ, ଲେନୋକ୍ସ-ଗାଷ୍ଟାଉଟ ଏବଂ ଡ୍ରାଭେଟ୍ ସିଣ୍ଡ୍ରୋମରେ ଇତ୍ୟାଦି ରୋଗମାନଙ୍କର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ । [୧୪] [୧୫] [୧୨] ଏହା କ୍ଲୋବାଜାମ ସହିତ ଏକତ୍ର ବ୍ୟବହୃତ ହୁଏ । [୧୬] ଏହା ପାଟିରେ ଦିଆଯାଏ । [୧୬] ୨୦୧୯ ସୁଦ୍ଧା ଉଦ୍‌ବେଗ, ସାଇକୋସିସ୍ କିମ୍ବା ଯନ୍ତ୍ରଣା ପାଇଁ ଏହାର ବ୍ୟବହାରକୁ ସମର୍ଥନ କରିବା ପାଇଁ ପ୍ରମାଣ ପର୍ଯ୍ୟାପ୍ତ ନୁହେଁ । [୧୭] [୧୮]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଉତ୍ତେଜନା, ତରଳ ଝାଡ଼ା, ଥକାପଣ, ଶୋଇବାରେ ଅସୁବିଧା ଏବଂ ରାସ ଅନ୍ତର୍ଭୁକ୍ତ । [୧୪] ଅନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଯକୃତ ସମସ୍ୟା ଏବଂ ଆତ୍ମହତ୍ୟା ଅନ୍ତର୍ଭୁକ୍ତ ହୋଇପାରେ । [୧୨] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର ଶିଶୁର କ୍ଷତି କରିପାରେ । [୨] ଏହାର କାର୍ଯ୍ୟଶୈଳୀ ସଂପୂର୍ଣ୍ଣ ସ୍ପଷ୍ଟ ନୁହେଁ । [୧୨] ଏହାର ଟେଟ୍ରାହାଇଡ୍ରୋକାନାବିନୋଲ (THC) ପରି ସମାନ ସାଇକୋଆକ୍ଟିଭ୍ ଗୁଣ ନାହିଁ । [୧୯]

୧୯୪୦ରେ କାନନାବିଡିଓଲ ଆବିଷ୍କୃତ ହୋଇଥିଲା। [୧୨] ଏହା ୨୦୧୮ରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏବଂ ୨୦୧୯ରେ ୟୁରୋପରେ ଚିକିତ୍ସା ପାଇଁ ଅନୁମୋଦିତ ହୋଇଥିଲା। [୧୨] [୧୨] ଯୁକ୍ତରାଷ୍ଟରେ ୨୦୨୧ରେ ଏହାର ୧୦୦ମିଗ୍ରା/ମିଲି ଦ୍ରବଣର ୩୦୦ମିଲିର ମୂଲ୍ୟ ୪୬୦୦ ଡଲାର ଥିଲା । [୨୦] ଏହା କାନାବିସ୍ ସାଟିଭା ଗଛରି ତିଆରି ହୁଏ । [୧୯] କିଛି ଲୋକ ଏହାକୁ ସିବିଡି (CBD) ତେଲ ଆକାରରେ ବ୍ୟବହାର କରନ୍ତି ଯେଉଁଥିରେ ସାଧାରଣତ ନିମ୍ନ ସ୍ତରର ଟିଏଚସି (THC) ଥାଏ । [୧୮]

ଆଧାର

[ସମ୍ପାଦନା]
  1. ↑ "Epidyolex". Therapeutic Goods Administration (TGA). 29 September 2020. Archived from the original on 30 October 2021. Retrieved 30 September 2020.
  2. ↑ ୨.୦ ୨.୧ ୨.୨ "Epidiolex- cannabidiol solution". DailyMed. 26 August 2020. Archived from the original on 25 February 2021. Retrieved 11 September 2020.
  3. ↑ "cannabidiol (CHEBI:69478)". www.ebi.ac.uk. Archived from the original on 2021-05-12. Retrieved 2021-10-30.
  4. ↑ "Epidyolex EPAR". European Medicines Agency (EMA). 24 June 2019. Archived from the original on 9 August 2021. Retrieved 11 September 2020. Text was copied from this source which is copyrighted by the European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  5. ↑ "Epidyolex 100 mg/ml oral solution - Summary of Product Characteristics (SmPC)". (emc). 28 August 2020. Archived from the original on 16 February 2021. Retrieved 11 September 2020.
  6. ↑ "Sativex Oromucosal Spray - Summary of Product Characteristics (SmPC)". (emc). 25 August 2020. Archived from the original on 4 February 2021. Retrieved 11 September 2020.
  7. ↑ "LeafPro CBDmed Oil FS QP 20%- cannabidiol oil". DailyMed. 9 March 2020. Archived from the original on 1 November 2021. Retrieved 11 September 2020.
  8. ↑ Perucca E, Bialer M (5 June 2020). "Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications". CNS Drugs. 34 (8): 795–800. doi:10.1007/s40263-020-00741-5. PMID 32504461. S2CID 219313952.
  9. ↑ Scuderi C, Filippis DD, Iuvone T, Blasio A, Steardo A, Esposito G (May 2009). "Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders". Phytotherapy Research (Review). 23 (5): 597–602. doi:10.1002/ptr.2625. PMID 18844286. S2CID 21836765. Archived from the original on 2021-04-11. Retrieved 2021-10-30.
  10. ↑ Devinsky O, Cilio MR, Cross H, Fernandez-Ruiz J, French J, Hill C, et al. (June 2014). "Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders". Epilepsia. 55 (6): 791–802. doi:10.1111/epi.12631. PMC 4707667. PMID 24854329.
  11. ↑ "cannabidiol (CHEBI:69478)". www.ebi.ac.uk. Archived from the original on 2021-05-12. Retrieved 2021-10-30.
  12. ↑ ୧୨.୦୦ ୧୨.୦୧ ୧୨.୦୨ ୧୨.୦୩ ୧୨.୦୪ ୧୨.୦୫ ୧୨.୦୬ ୧୨.୦୭ ୧୨.୦୮ ୧୨.୦୯ ୧୨.୧୦ ୧୨.୧୧ ୧୨.୧୨ ୧୨.୧୩ ୧୨.୧୪ ୧୨.୧୫
  13. ↑ "Epidiolex- cannabidiol solution". DailyMed. 26 August 2020. Archived from the original on 25 February 2021
  14. ↑ ୧୪.୦ ୧୪.୧ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 326. ISBN 978-0857114105.
  15. ↑ "Cannabidiol Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 27 October 2020. Retrieved 7 January 2022.
  16. ↑ ୧୬.୦ ୧୬.୧ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 326. ISBN 978-0857114105.
  17. ↑ Black N, Stockings E, Campbell G, Tran LT, Zagic D, Hall WD, Farrell M, Degenhardt L (December 2019). "Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis". The Lancet. Psychiatry. 6 (12): 995–1010. doi:10.1016/S2215-0366(19)30401-8. PMC 6949116. PMID 31672337. {{cite journal}}: Unknown parameter |displayauthors= ignored (|display-authors= suggested) (help)
  18. ↑ ୧୮.୦ ୧୮.୧ VanDolah HJ, Bauer BA, Mauck KF (September 2019). "Clinicians' Guide to Cannabidiol and Hemp Oils". Mayo Clinic Proceedings. 94 (9): 1840–1851. doi:10.1016/j.mayocp.2019.01.003. PMID 31447137.
  19. ↑ ୧୯.୦ ୧୯.୧ Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimarães FS (December 2012). "Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders". Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences (Review). 367 (1607): 3364–78. doi:10.1098/rstb.2011.0389. PMC 3481531. PMID 23108553.
  20. ↑ "Epidiolex Prices and Epidiolex Coupons - GoodRx". GoodRx. Archived from the original on 5 August 2021. Retrieved 7 January 2022.
"https://or.wikipedia.org/w/index.php?title=କାନାବିଡିଓଲ&oldid=506823"ରୁ ଅଣାଯାଇଅଛି